Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-2870 versus physician's choice chemotherapy in previously treated endometrial cancer
MOH_2023-11-19_013055Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Nov 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of sacituzumab tirumotecan in endometrial cancer (EC) (3 arms), sponsored by Merck & Co. Primary endpoints: Progression-free survival and Overall survival. Started Nov 2023; status: active, not recruiting.
02
Drugs
sacituzumab tirumotecan
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on MOH_2023-11-19_013055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-11-19_013055.